glyburide has been researched along with Burkholderia pseudomallei Infection in 4 studies
Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide
glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We further show, for the first time in any model of sepsis, that glyburide acts as an anti-inflammatory agent by reducing IL1β secretion accompanied by diminished cellular influx and reduced bacterial dissemination to distant organs." | 3.79 | Glyburide reduces bacterial dissemination in a mouse model of melioidosis. ( Bast, A; Breitbach, K; de Jong, HK; Hoogendijk, AJ; Kager, LM; Koh, GC; Krause, K; Peacock, SJ; Steinmetz, I; van der Poll, T; Weehuizen, TA; Wiersinga, WJ, 2013) |
| "The major risk factor for melioidosis, an infectious disease caused by B." | 1.43 | Glibenclamide impairs responses of neutrophils against Burkholderia pseudomallei by reduction of intracellular glutathione. ( Ato, M; Bancroft, GJ; Kewcharoenwong, C; Lertmemongkolchai, G; Nithichanon, A; Rinchai, D, 2016) |
| "Type 2 diabetes mellitus is a major risk factor for melioidosis, which is caused by Burkholderia pseudomallei." | 1.39 | Glibenclamide reduces pro-inflammatory cytokine production by neutrophils of diabetes patients in response to bacterial infection. ( Ato, M; Bancroft, GJ; Kewcharoenwong, C; Lertmemongkolchai, G; Rinchai, D; Suwannasaen, D; Utispan, K, 2013) |
| "Glyburide is an oral hypoglycemic agent used to treat diabetes mellitus." | 1.37 | Glyburide is anti-inflammatory and associated with reduced mortality in melioidosis. ( Chaowagul, W; Chierakul, W; Day, NP; Dougan, G; Koh, GC; Lee, SJ; Limmathurotsakul, D; Mahavanakul, W; Maude, RR; Peacock, SJ; Schreiber, MF; van der Poll, T; White, NJ; Wiersinga, WJ; Wuthiekanun, V, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Koh, GC | 2 |
| Weehuizen, TA | 1 |
| Breitbach, K | 1 |
| Krause, K | 1 |
| de Jong, HK | 1 |
| Kager, LM | 1 |
| Hoogendijk, AJ | 1 |
| Bast, A | 1 |
| Peacock, SJ | 2 |
| van der Poll, T | 2 |
| Steinmetz, I | 1 |
| Wiersinga, WJ | 2 |
| Kewcharoenwong, C | 2 |
| Rinchai, D | 2 |
| Utispan, K | 1 |
| Suwannasaen, D | 1 |
| Bancroft, GJ | 2 |
| Ato, M | 2 |
| Lertmemongkolchai, G | 2 |
| Nithichanon, A | 1 |
| Maude, RR | 1 |
| Schreiber, MF | 1 |
| Limmathurotsakul, D | 1 |
| Wuthiekanun, V | 1 |
| Lee, SJ | 1 |
| Mahavanakul, W | 1 |
| Chaowagul, W | 1 |
| Chierakul, W | 1 |
| White, NJ | 1 |
| Day, NP | 1 |
| Dougan, G | 1 |
4 other studies available for glyburide and Burkholderia pseudomallei Infection
| Article | Year |
|---|---|
Glyburide reduces bacterial dissemination in a mouse model of melioidosis.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Burkholderia pseudomallei; Ceftazidime; Di | 2013 |
Glibenclamide reduces pro-inflammatory cytokine production by neutrophils of diabetes patients in response to bacterial infection.
Topics: Burkholderia pseudomallei; Diabetes Mellitus, Type 2; Disease Susceptibility; Glyburide; Humans; Hyp | 2013 |
Glibenclamide impairs responses of neutrophils against Burkholderia pseudomallei by reduction of intracellular glutathione.
Topics: Acetylcysteine; Adult; Burkholderia pseudomallei; Case-Control Studies; Cell Movement; Cytokines; Di | 2016 |
Glyburide is anti-inflammatory and associated with reduced mortality in melioidosis.
Topics: Adult; Anti-Inflammatory Agents; Burkholderia pseudomallei; Cohort Studies; Female; Glyburide; Human | 2011 |